Clinical trial · Interventional
Pancreatic Enzyme Suppletion in Pancreatic Cancer
Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy
NCT01401387CI-TRIAL-00009545EPCwithdrawnPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): study never started
Summary
Brief summary (as posted)
This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine pancreatic insufficiency during their disease process.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Pancreas | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
| Normal Pancreatic Exocrine Function | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Timing of start treatment with pancreatic enzymes | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard treatment
- description
- Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
- interventionNames
- Other: Timing of start treatment with pancreatic enzymes
- type
- ACTIVE_COMPARATOR
- label
- Preventive treatment
- description
- Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
- interventionNames
- Other: Timing of start treatment with pancreatic enzymes
Primary outcomes (1)
- measure
- To evaluate if prescribing pancreatic enzymes in patients with pancreatic cancer leads to a decrease in weight loss.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adenocarcinoma of the pancreas (histologically confirmed) * Normal exocrine pancreatic function (Fecal Elastase test \> 0.2 mg/g) * Capable and willing to follow instructions given by the physician. Exclusion Criteria: * Other causes of fat malabsorption (celiac disease, IBD, and major gastrointestinal surgery). * \< 18 years.
References
Publications (0)
Data not yet available
No reference posted for this study.